|Articles|March 24, 2023

World Tuberculosis Day 2023: The State of the Infectious Disease Today

Author(s)Nina Cosdon

March 24 is World Tuberculosis Day. Here’s a brief history of the second deadliest infectious disease, and how it affects the world today.

Every March 24, World Tuberculosis Day raises awareness about one of the oldest and deadliest infectious diseases. Tuberculosis (TB) is a serious lung infection that spreads in the droplets released by coughing and sneezing.

On this day in 1882, Robert Koch identified the Mycobacterium tuberculosis bacterium that causes tuberculosis. A hundred years later, World TB Day was first observed on March 24, 1982.

The term “tuberculosis” was first used by Johann Schonlein in 1834, but the US Centers for Disease Control and Prevention (CDC) estimates it has afflicted mammals for nearly 3 million years. Tuberculosis was called “phthisis” in ancient Greek, “tabes” in ancient Latin, and “schachepheth” in ancient Hebrew. TB was also known as “white death” in the 1700s, due to the pale appearance of afflicted patients.

Today, tuberculosis is the second deadliest infectious disease in the world; the first is COVID-19. Like COVID-19, TB is a respiratory disease that spreads from person to person. Unlike COVID-19, however, TB transmission requires prolonged exposure to an infected individual.

The Mycobacterium tuberculosis bacterium initially attacks the lungs, where it settles and begins to grow. From there, TB can move through the bloodstream to affect the kidney, spine, and brain, potentially proving fatal. People most at risk for TB disease have usually just been infected with Mycobacterium tuberculosis bacteria, or have a weakened immune system.

The most common symptoms of TB are chest pain, a bad cough that lasts 3 weeks or longer, and coughing up blood or phlegm from deep in the lungs. Other symptoms may be weakness and fatigue, chills, fever, night sweats, loss of appetite, and weight loss. The weight loss associated with TB led to its historical nickname “consumption.”

Not everyone infected with TB becomes sick, leading to the distinction between latent tuberculosis infection (LTBI) and TB disease. The CDC estimates approximately 13 million people in the US are living with inactive TB.

People with asymptomatic LTBI cannot transmit TB to others. Most infections are asymptomatic, but about 10% of people with LTBI progress to active disease later in life. People at high risk for developing TB have several treatment options for LTBI.

The CDC notes the risk of TB is higher among individuals who:

  • Were born in or frequently travel to countries where TB is common, including those in Asia, Africa, and Latin America
  • Live or used to live in large group settings where TB is more common, such as homeless shelters, prisons, or jails
  • Recently spent time with someone who has active TB disease
  • Have a weaker immune system because of certain medications or health conditions such as diabetes, cancer, and HIV
  • Work in places with high risk for TB transmission, such as hospitals, homeless shelters, correctional facilities, and nursing homes

In 2020, the World Health Organization (WHO) estimated 10 million people contracted tuberculosis, and 1.5 million died from TB. Globally, TB is the thirteenth leading cause of death and the second most fatal infectious disease (after COVID-19 and above HIV/AIDS).

TB is curable and preventable but is often overlooked due to being difficult to diagnose in children and adolescents. The Bacillus Calmette-Guérin (BCG) vaccine is used to immunize children against TB, but its protection wanes over time. In the US, the BCG vaccine is not widely recommended and is administered only to select people who meet specific criteria.

Overall, TB rates are falling by approximately 2% each year, but this is complicated by the rise of multidrug-resistant tuberculosis (MDR-TB). The WHO calls MDR-TB “a public health crisis and a global security threat.” Antimicrobial resistance is a major problem worldwide, occurring when dangerous pathogens are treated with too many antibiotics and mutate to develop immunity.

For more tuberculosis news and developments, click here.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.